These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30522346)

  • 1. Ertugliflozin: A New Option in the SGLT-2 Inhibitor Market for the Treatment of Type 2 Diabetes Mellitus.
    Powell J; Garland SG
    Ann Pharmacother; 2019 May; 53(5):478-485. PubMed ID: 30522346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus.
    Yang J
    Expert Rev Clin Pharmacol; 2018 Aug; 11(8):747-753. PubMed ID: 30025475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ertugliflozin for the treatment of type 2 diabetes.
    Sharma R; Razdan K; Kuhad A; Kuhad A
    Drugs Today (Barc); 2019 Mar; 55(3):167-175. PubMed ID: 30938372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
    Pratley RE; Eldor R; Raji A; Golm G; Huyck SB; Qiu Y; Sunga S; Johnson J; Terra SG; Mancuso JP; Engel SS; Lauring B
    Diabetes Obes Metab; 2018 May; 20(5):1111-1120. PubMed ID: 29266675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus.
    Liu J; Tarasenko L; Pong A; Huyck S; Patel S; Hickman A; Mancuso JP; Ellison MC; Gantz I; Terra SG
    Curr Med Res Opin; 2020 Jul; 36(7):1097-1106. PubMed ID: 32324065
    [No Abstract]   [Full Text] [Related]  

  • 6. Ertugliflozin as a monotherapy for the treatment of type 2 diabetes.
    Hu J; Deng A; Zhao Y
    Expert Opin Pharmacother; 2018 Nov; 19(16):1841-1847. PubMed ID: 30223693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Khan P; Venkatesh S; Parveen R; Mishra P; Jain S; Agarwal N
    Expert Opin Pharmacother; 2023; 24(18):2199-2210. PubMed ID: 37955156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
    Terra SG; Focht K; Davies M; Frias J; Derosa G; Darekar A; Golm G; Johnson J; Saur D; Lauring B; Dagogo-Jack S
    Diabetes Obes Metab; 2017 May; 19(5):721-728. PubMed ID: 28116776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.
    Cinti F; Moffa S; Impronta F; Cefalo CM; Sun VA; Sorice GP; Mezza T; Giaccari A
    Drug Des Devel Ther; 2017; 11():2905-2919. PubMed ID: 29042751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.
    Amin NB; Wang X; Jain SM; Lee DS; Nucci G; Rusnak JM
    Diabetes Obes Metab; 2015 Jun; 17(6):591-598. PubMed ID: 25754396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ertugliflozin: First Global Approval.
    Markham A
    Drugs; 2018 Mar; 78(4):513-519. PubMed ID: 29476348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ertugliflozin Compared to Placebo in Patients With Type 2 Diabetes: An Updated Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Alam MS; Talukder SK; Hannan MA; Dutta D; Nagendra L; Selim S
    J Diabetes Res; 2024; 2024():5553327. PubMed ID: 39354951
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies.
    Liu J; Tarasenko L; Terra SG; Huyck S; Wu L; Pong A; Calle RA; Gallo S; Darekar A; Mancuso JP
    Diab Vasc Dis Res; 2019 Sep; 16(5):415-423. PubMed ID: 31081371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials.
    Zhang F; Wang W; Hou X
    J Diabetes Investig; 2022 Mar; 13(3):478-488. PubMed ID: 34610204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus.
    Liu J; Tarasenko L; Pong A; Huyck S; Wu L; Patel S; Hickman A; Mancuso JP; Gantz I; Terra SG
    Curr Med Res Opin; 2020 Aug; 36(8):1277-1284. PubMed ID: 32324082
    [No Abstract]   [Full Text] [Related]  

  • 17. Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor.
    Fediuk DJ; Nucci G; Dawra VK; Cutler DL; Amin NB; Terra SG; Boyd RA; Krishna R; Sahasrabudhe V
    Clin Pharmacokinet; 2020 Aug; 59(8):949-965. PubMed ID: 32337660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
    Cowart K; Carris NW
    Expert Opin Pharmacother; 2021 Feb; 22(2):163-165. PubMed ID: 32962443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials.
    Liu J; Pong A; Gallo S; Darekar A; Terra SG
    Cardiovasc Diabetol; 2019 May; 18(1):59. PubMed ID: 31064361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
    Rosenstock J; Frias J; Páll D; Charbonnel B; Pascu R; Saur D; Darekar A; Huyck S; Shi H; Lauring B; Terra SG
    Diabetes Obes Metab; 2018 Mar; 20(3):520-529. PubMed ID: 28857451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.